Drug Trial Radar · NCT03575052
A Safety Study of Pimavanserin in Adult and Elderly Subjects Experiencing Neuropsychiatric Symptoms Related to Neurodegenerative Disease
Last checked: Nov 20, 2026Latest source record: Dec 31, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
784
Actual
Start
May 21, 2018
Primary completion
May 6, 2022
Study completion May 6, 2022
Sponsor
- Lead sponsor
- ACADIA Pharmaceuticals Inc.Industry
- Sponsor type
- Industry
- First posted
- Jul 2, 2018
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 60 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess the safety and tolerability of pimavanserin compared to placebo in adult and elderly subjects with neuropsychiatric symptoms related to neurodegenerative disease.
Conditions
- Neuropsychiatric Symptoms Related to Neurodegenerative Disease
Interventions
PimavanserinDrug
Pimavanserin 34 mg total daily dose, tablets, once daily by mouth (provided as two 17 mg NUPLAZID® tablets)
PlaceboDrug
Placebo, tablets, once daily by mouth (provided as two placebo tablets)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Treatment-emergent Adverse Events (TEAEs)Time frame: Treatment Period: 8 weeks
Locations
104 sites in 12 countries. Site status is shown where the registry gives one.
Cognitive Clinical Trials
Gilbert, Arizona
ATP Clinical Research, Inc.
Costa Mesa, California
Syrentis Clinical Research
Santa Ana, California
Indago Research & Health Center Inc
Hialeah, Florida
Reliable Clinical Research, LLC
Hialeah, Florida
Axcess Medical Research
Loxahatchee Groves, Florida
Premier Clinical Research Institute, Inc.
Miami, Florida
Global Medical Institutes
Miami, Florida
Future Care Solution, LLC
Miami, Florida
MediClear Medical & Research Center, Inc.
Miami, Florida
Novel Clinical Research LLC
Miami, Florida
Laszlo J Mate, MD, PA
North Palm Beach, Florida
University of South Florida
Tampa, Florida
Synexus Clinical Research US
The Villages, Florida
Boston Center Memory
Newton, Massachusetts
Cognitive Clinical Trials LLC
Papillion, Nebraska
The NeuroCognitive Institute
Mount Arlington, New Jersey
UNC Hospital
Chapel Hill, North Carolina
Insight Clinical Trials LLC
Shaker Heights, Ohio
Suburban Research Associates
Media, Pennsylvania
Central for Biomedical Research, LLC
Knoxville, Tennessee
Centre for Mental Health Prof. Dr. Ivan Temkov, Lazur Compl., Park Ezero
Burgas, Bulgaria
UMHAT Psych clin for gen psychiatry and addictions
Pleven, Bulgaria
DCC Sv. Vrach and Sv. Sv. Kozma and Damyan
Sofia, Bulgaria
Diagnostic Consultative Centre, 2, N. Vaptzarov Street
Varna, Bulgaria
Diagnostic Consultative Centre-Mladost-Psychiatry, 15, Republika Blvd
Varna, Bulgaria
Mental Health Center Vratza EOOD, 1 Belasitsa St
Vratsa, Bulgaria
Centro de Investigaciones del Sistema Nervioso
Bogotá, Colombia
E.S.E. Hospital Mental de Antioquia
Bello, Antioquia, Colombia
Centr Investigaciones y Proyectos en Neurociencias
Barranquilla, Atlántico, Colombia
Psynapsis Salud Mental S.A.
Pereira, Risaralda Department, Colombia
BRAIN-SOULTHERAPY s.r.o., , Lekarna Jalta, Namesti Jana Masaryka 3113
Kladno, Czechia
Fakultni nemocnice Olomouc
Olomouc, Czechia
A-shine s.r.o./ Lekarna Centrum
Pilsen, Czechia
AD71, s.r.o.,/Hostivarska Iekarna
Prague, Czechia
Axon Clinical
Prague, Czechia
Neuropsychiatrie, s.r.o., Lekarna 6ka, Fajtlova 1
Prague, Czechia
AD71, s.r.o., /,Lekarna DPS Recruiting
Říčany, Czechia
Petre Sarajishvili Institute of Neurology LLC
Tbilisi, Georgia
Pineo Medical Ecosystem LTD
Tbilisi, Georgia
Showing 40 of 104 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.